Results 71 to 80 of about 14,520 (202)

Ferroptosis in breast cancer: From adipocyte–immune–iron regulation to therapeutic application

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
Ferroptosis in breast cancer is regulated by an integrated adipocyte–immune–iron network rather than by tumour‐intrinsic pathways alone. Adipocyte‐derived lipid substrates and redox metabolites, immune‐cell‐mediated cytokine signalling and iron‐dependent oxidative stress collectively shape a dynamic ferroptosis ecosystem that can shift tumours towards ...
Juan Sun, Yang Qu, Ru Yao, Yidong Zhou
wiley   +1 more source

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

, 2010
peer reviewedPURPOSE: We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior ...
Sally Garnett, Didier Verhoeven, Lubos Petruzelka, Bondarenko, Igor N, Torres, Roberto, Francisco Sapunar, Pendergrass, Kelly, José L. Pedrini, Lichinitser, Mikhail R, Di Leo, Angelo, Martin, Miguel, Miguel Martin, Justin P.O. Lindemann, Sapunar, Francisco, Rustem Khasanov, Mikhail R. Lichinitser, Roberto Torres, Jerusalem, Guy, Pedrini, Jose L, Smirnova, Iya, Petruzelka, Lubos, Khasanov, Rustem, Iya Smirnova, Angelo Di Leo, Guy Jerusalem, Garnett, Sally, Verhoeven, Didier, Lindemann, Justin P O, Igor N. Bondarenko, Kelly Pendergrass   +29 more
core   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, Volume 2, Issue 2, June 2026.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells

Cellular Physiology and Biochemistry, 2018
Background/Aims: Blocking estrogen signaling with endocrine therapies (Tamoxifen or Fulverstrant) is an effective treatment for Estrogen Receptor-α positive (ER+) breast cancer tumours.
Pratima Basak, Sumanta Chatterjee, Vasudeva Bhat, Alice Su, Hyerang Jin, Victoria Lee-Wing, Qian Liu, Pingzhao Hu, Leigh C Murphy, Afshin Raouf   +9 more
doaj   +1 more source

Reduced folate receptor alpha (FOLR1) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab‐soravtansine therapy

The Journal of Pathology: Clinical Research, Volume 12, Issue 3, May 2026.
Abstract Mirvetuximab‐soravtansine (MIRV‐S) is an antibody‐drug conjugate targeting folate receptor alpha (FOLR1). MIRV‐S is approved for the treatment of FOLR1‐positive, platinum‐resistant ovarian carcinoma. Patient eligibility is determined by immunohistochemistry (IHC) using a companion diagnostic (CDx) assay (FOLR1‐2.1, Ventana).
Annika Nasdala, Leonie D Kandt, Martin Radner, Nora Schaumann, Malte Gronewold, Pia Hillmann, Henriette Christgen, Jens Hachenberg, Elna Kuehnle, Christian Hartmann, Matthias Christgen   +10 more
wiley   +1 more source

Risposta rapida e duratura a fulvestrant in paziente con malattia metastatica e impegno viscerale

, 2012
Caso clinico che descrive una paziente in post-menopausa con diagnosi di recidiva linfonodale, polmonare e scheletrica di carcinoma duttale infiltrante a recettori estrogenici positivi, diagnosticata in corso di ormonoterapia adiuvante con inibitore non ...
Gravina, A, PIACENTINI, Federico, Crivellari, D, Fanelli, F, Palumbo, R   +4 more
core  

Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?

, 2006
Over the past two decades, much research has focused on developing new antiestrogens that lack estrogen agonist effects and have improved efficacy and tolerability profiles compared with tamoxifen. As all patients eventually become resistant to tamoxifen,
A. HOWELL, Howell, A.; id_orcid
core   +1 more source

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

, 2019
BACKGROUND: In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor-positive, human epidermal ...
Beck J. T., Sondhi M., Jerusalem G., Chakravartty, Arunava, Sonke, Gabe S., Nusch A., De La Cruz-Merino L., Esteva, Francisco J, Rodriguez-Lorenc, Karen, Esteva F. J., Sonke, Gabe S, Esteva, Francisco J., Sonke G. S., Slamon, Dennis J., Bianchi G. V., Sondhi, Manu, Wang Y., Im S. -A., Beck, J Thaddeus, Martin, Miguel, Neven P., Chakravartty A., Nusch, Arnd, De Laurentiis M., Bianchi, Giulia V., De Laurentiis, Michelino, Jerusalem, Guy, Petrakova K., Rodriguez-Lorenc K., Bianchi, Giulia V, De la Cruz-Merino, Luis, Beck, J. Thaddeus, Fasching, Peter A, Slamon, Dennis J, Pivot X., Chia, Stephen, Neven, Patrick, Fasching, Peter A., Chia S., Petrakova, Katarina, Taran, Tetiana, Slamon D. J., Pivot, Xavier, Taran T., Martin M., Im, Seock-Ah, Wang, Yingbo, Fasching P. A.   +47 more
core   +1 more source

Randomised trial of fulvestrant plus vistusertib versus fulvestrant plus everolimus versus fulvestrant alone in hormone-receptor-positive metastatic breast cancer (MANTA)

, 2019
Importance: Randomised clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mTORC1 complex but not mTORC2, which can set off a activating feedback loop via mTORC2.
Lee, K, Conibear, J, Moosa, A, Antonia, P, Schmid, P, Pendergast, A, Makris, A, Ferreira, M, Cortes, J, Kristeleit, H, Nemsdze, G, Kuemmel, S, Schenker, M, Brunt, A, Mathias, Z, Carike, C, Kendall, A, Sarker, S-J, Ruiz, I, Harper-Wynne, C, Cheryl, L, Mahr, K, Chan, S, Sohn, J, Dubey, S, Oelmann, E, Shepherd, C, Sohn, C, Grenier, J, Kelly, M, Brown, J, Marosics, P   +31 more
core  

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

, 2019
BackgroundFulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC).MethodsMeta-analysis of randomized controlled trials (RCTs)
Ellis, Matthew, Campbell, Christine, Di Leo, Angelo, Bradbury, Ian, Pritchard, Kathleen I., Ohno, Shinji, Robertson, John F. R., Jiang, Zefei   +7 more
core   +1 more source